Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and ExpositionGlobeNewsWire • 12/13/21
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13GlobeNewsWire • 12/09/21
Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche's Anti-PD-L1 Checkpoint Inhibitor AtezolizumabGlobeNewsWire • 12/08/21
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive LymphomasGlobeNewsWire • 11/22/21
Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial KillingGlobeNewsWire • 11/12/21
Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational ProgressGlobeNewsWire • 11/10/21
Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01GlobeNewsWire • 11/08/21
Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid LeukemiaGlobeNewsWire • 11/04/21
Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13GlobeNewsWire • 11/04/21
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/03/21
Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021GlobeNewsWire • 10/29/21
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of CancerGlobeNewsWire • 10/01/21
Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 09/08/21